Large surface area microparticle docetaxel shows promise in NMIBC - Urology Times
Study findings presented during the 2021 AUA annual meeting showed that large surface area microparticle docetaxel (LSAM-DTX; NanoDoce) is safe with early signs of clinical activity in patients with high-risk non–muscle invasive bladder cancer (NMIBC). 1 Among the 19 patients who received LSAM-DTX at any dose level in the phase 1/2 trial (NCT03636256), the 3-month complete response (CR) rate was 68%. The 6-month durability in 13 evaluable patients who had a CR at 3 months was 62% and the 12-month durability in this group was 31%. "LSAM-DTXs are large surface area microparticles of pure drug in powder form," explained Max Kates, MD, the director of the Bladder Cancer Program and an assistant professor of urology at the Johns Hopkins University School of Medicine in Baltimore, Maryland. "The microparticles are formed using supercritical precipitation technology, then suspended in saline prior to use. The uniqueness of this technology relative to other particle engineering ...